Yekta Çulpan

Yekta Çulpan

Auto-generated profile, based on publicly available information

Yekta Çulpan

Marmara University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2022 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
RGRezzan Gülhan
Rezzan Gülhan
EEEmel Eryüksel
Emel Eryüksel
MOMedine Gülçebi İdRiz Oğlu
Medine Gülçebi İdRiz Oğlu
YÇYekta Çulpan
Yekta Çulpan
AHAylin Toplu Hocaoğlu
Aylin Toplu Hocaoğlu
FOFiliz Onat
Filiz Onat
This prospective observational study describes the pharmacokinetic characteristics of favipiravir in adult patients hospitalized for mild to moderate COVID‐19 with a positive RT‐PCR test. Favipiravir was administered for 5 days, with a loading dose of 3200 mg and a maintenance dose of 1200 mg/day. Serial blood samples were collected on Day 2 and Day 4 of the therapy. Laboratory findings of the patients (n = 21) and in‐hospital mortality were recorded. Favipiravir concentrations exhibited substantial variability and a significant decrease during the treatment of COVID‐19. The median favipiravir trough concentration (C0‐trough) on Day 2 was 21.26 (interquartile range [IQR], 8.37–30.78) μg/mL, whereas it decreased significantly to 1.61 (IQR, 0.00–6.41) μg/mL on Day 4, the area under the concentration–time curve decreased by 68.5%. Day 2 C0‐trough of female patients was higher than male patients. Our findings indicate that favipiravir concentrations show significant variability during the treatment of COVID‐19 and therapeutic drug monitoring may be necessary to maintain targeted concentrations.

1 November 2022 in The Anatolian Journal of Cardiology
Verified
Journal Article
Open access
YCYekta Culpan
Yekta Culpan
IKIrem Kececi
Irem Kececi
ISIrem Sandikci
Irem Sandikci
SGSeyda Gokce
Seyda Gokce
HGHande Goker
Hande Goker
RGRezzan Gulhan
Rezzan Gulhan
Recent findings suggest that fluoroquinolones, most prescribed antibiotic to treat various infections, have increased abdominal aortic aneurysm formation. We aimed to investigate the relation of the development of abdominal aortic aneurysm and the duration of ciprofloxacin use. Male Sprague–Dawley rats were divided into 2 groups to administer saline to the control groups and CaCl2 to the aneurysm groups. These groups were then divided into 3 subgroups: intraperitoneal saline, ciprofloxacin for 2 weeks, and ciprofloxacin for 4 weeks. At the end of 4 weeks, the diameter of abdominal aorta was determined by ultrasonography and animals were sacrificed to obtain abdominal aorta specimens. Elastic fiber fracture, tunica media layer thickness, and aortic tissue damage were evaluated histologically. Aortic diameter of control-saline (2.15 mm ± 0.06), control-2 weeks (2.25 mm ± 0.06), and control-4 weeks (3.31 mm ± 0.09) ciprofloxacin groups was significantly different (P < .0001). Also, aortic diameter of aneurysm-saline (2.07 mm ± 0.02), aneurysm-2 weeks ciprofloxacin (3.33 mm ± 0.64), and aneurysm-4 weeks ciprofloxacin (8.55 mm ± 1.70) groups showed significant increase in aortic diameter with increasing duration of ciprofloxacin use (P < .01). A significant difference was found between the control-saline (0.00 ± 0.00), control-2 weeks (1.50 ± 0.33), and control-4 weeks ciprofloxacin groups (1.57 ± 0.20) in the histological aneurysm scores (P < .001). Aortic tunica media thickness did not change between control-saline and control-ciprofloxacin groups (P > .05). The study showed that ciprofloxacin caused injury in the aortic wall but not a significant change in the thickness of the aortic tunica media layer. The duration of ciprofloxacin use was important in the development of aneurysm and aneurysm severity.

8 September 2025
Verified
Book Chapter
Closed access
PDF file
NTNurdan Tekin
Nurdan Tekin
YÇYekta Çulpan
Yekta Çulpan
RGRezzan Gülhan
Rezzan Gülhan
Neurodegenerative diseases comprise a wide range of debilitating disorders, which are characterized by progressive and irreversible loss of neurons and/or glial cells in the specific regions of the brain and spinal cord. They may result in abnormalities in the control of movement, motor weakness, impairment of memory, and cognitive ability such as seen in Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). This chapter provides an overview of currently available pharmacotherapy options that are used in the treatment of these disorders. <!----> <!----> <!----> <!---->

31 May 2024 in Marmara Medical Journal
Verified
Journal Article
Open access
PDF file
YÇYekta Çulpan
Yekta Çulpan
LOLara Ozden
Lara Ozden
YGYakup Gozderesi
Yakup Gozderesi
BKBeril Kocak
Beril Kocak
ZBZeynep Hazal Baltaci
Zeynep Hazal Baltaci
RGRezzan Gülhan
Rezzan Gülhan
Objective: Type 2 diabetes mellitus patients have been reported to have a higher incidence of Parkinson’s disease. This study aimed to explore the effect of advanced glycation end products precursor methylglyoxal (MGO) on the pathophysiology of Parkinson’s disease in a rotenone model. Materials and Methods: Adult female Wistar rats (n=42) were divided into four groups. Rotenone toxicity was assessed by daily weight measurements and mortality rates. Effect of MGO on blood glucose was evaluated. Locomotor activity, rearing, and rotarod tests were performed to evaluate motor functions, and for neurodegeneration, tyrosine hydroxylase immunoreactivity in the striatum and substantia nigra regions was assessed. Results: The mortality rate was 9% in the rotenone-applied rats. The mean weight, locomotor activity, rearing activity, and longest time spent on a rotarod were lower in the MGO+Rotenone group than in the Control group. Tyrosine hydroxylase immunoreactivity in the striatum rostral to the anterior commissure in the MGO+Rotenone group was lower than that in the Control and MGO groups. The number of tyrosine hydroxylase positive cells in the substantia nigra pars compacta was comparable among the groups. Conclusion: When nigrostriatal degeneration was triggered, MGO was found to worsen motor dysfunction and increase damage to dopaminergic neuron projections.